Archive · 26 Dec 2025
India's Economic Growth and Sectoral Developments in 2025
In 2025, India's economy grew strongly with low inflation and high GDP growth.
The country saw a lot of initial public offerings (IPOs) and more people investing in the stock market.
The insurance sector also grew, with more digital policies and better services.
The pharmaceutical industry made progress with new rules and innovations.
Sun Pharma, one of India's largest drugmakers, is aiming for mid- to high-single digit revenue growth in FY26.
They are focusing on research and development to strengthen their innovative medicines pipeline.
The company is also navigating policy developments in the US pharmaceutical market, which could impact their pricing strategies.
Overall, leaders in these sectors are optimistic about the future and want to make India a global leader in healthcare and life sciences by 2047.
They are focusing on improving quality, access, and innovation to achieve these goals.
India's economy grew by 8.2% in the July–September 2025 quarter, with a full-year GDP growth forecast of 7.3% for FY26.
Inflation fell to a record low of 0.25% in October 2025, leading to a series of interest rate cuts by the Reserve Bank of India.
The equity market saw a historic IPO boom, with over 86 IPOs raising ₹1.71 lakh crore between October 2024 and September 2025.
The insurance sector experienced significant growth, with a 10.4% increase in health insurance premiums and over 90% of retail policies issued digitally.
Sun Pharma aims for mid- to high-single digit revenue growth in FY26, focusing on innovation and R&D, with cumulative R&D spending reaching ₹320 billion.
- Who
- Indian economy, pharmaceutical industry, insurance sector, and capital markets
- What
- Economic growth, policy reforms, and sectoral advancements
- When
- 2025 and looking ahead to 2026
- Where
- India
- Why
- To achieve sustained economic growth, improve healthcare access, and boost innovation
- GDP Growth (July–September 2025)
- 8.2%
- Full-Year GDP Growth Forecast (FY26)
- 7.3%
- Inflation Rate (October 2025)
- 0.25%
- Policy Repo Rate (December 2025)
- 5.25%
- IPO Fundraising (October 2024–September 2025)
- ₹1.71 lakh crore
- Health Insurance Premium Growth (2025)
- 10.4%
- Total Premium Income (2025)
- ₹3.21-3.24 lakh crore
- Digital Policy Issuance (2025)
- Over 90% of retail policies
- Health Claims Processed Digitally (Urban Markets)
- 60-70%
- Licensed Insurance Intermediaries
- Over 30 lakh
- Sun Pharma FY26 Revenue Growth Target
- Mid- to high-single digit
- Sun Pharma R&D Spending (Cumulative)
- ₹320 billion
- Sun Pharma R&D Expenditure (FY25)
- 6.2% of sales
- Sun Pharma Q2 Net Profit (September 2025)
- ₹31.18 billion
- Sun Pharma Q2 Revenue (September 2025)
- ₹144.05 billion
- Sun Pharma Share Price (December 2025)
- ₹1,720.00
Sources
2026 & beyond: Indian pharma hinges hopes on innovation impetus & regulatory agility
GST reforms, RDI scheme strengthened Indian pharma in 2025, innovation & access key for 2026
Policy reforms, digital surge power Indias insurance sector in 2025: Leaders
From inflation control to IPO boom: Six forces driving India’s economy in 2025
Indian Pharmaceutical Industry Transformed By GST Reforms And Research Development In 2025
India sets 2026 health agenda: Drug quality, innovation, TB and obesity take centre stage
From Global Standards To AI-Integration, 2025 Was The Year Of Traditional Medicine Growth; Here's Why
2025: Landmark Year of Evidence-Based Growth & Global Leadership For India's Ayush Sector
Is India’s healthcare sector ready for execution in 2026?